RESUMO
OBJECTIVE: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies. DESIGN: Retrospective cohort study. SETTING: Seven US healthcare delivery systems. PARTICIPANTS: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter-defibrillator (ICD) for primary prevention. MEASUREMENTS: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0-3, 4-5, 6-7 and 8-16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy. RESULTS: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4-8), with 98% having at least two comorbidities. During a mean 2.2 years of follow-up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14-3.31] for 4-5 comorbidities; HR = 2.25 [95% CI = 1.25-4.05] for 6-7 comorbidities; and HR = 2.91 [95% CI = 1.54-5.50] for 8-16 comorbidities). Participants with 8-16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43-3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67-6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07-2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies. CONCLUSIONS: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
Assuntos
Desfibriladores Implantáveis , Multimorbidade , Disfunção Ventricular Esquerda/terapia , Idoso , Morte Súbita Cardíaca/prevenção & controle , Feminino , Humanos , Masculino , Prevenção Primária , Estudos Retrospectivos , Fatores de Risco , Estados UnidosRESUMO
BACKGROUND: Primary prevention implantable cardioverter-defibrillators (ICDs) reduce mortality in selected patients with left ventricular systolic dysfunction by delivering therapies (antitachycardia pacing or shocks) to terminate potentially lethal arrhythmias; inappropriate therapies also occur. We assessed device therapies among adults receiving primary prevention ICDs in 7 healthcare systems. METHODS AND RESULTS: We linked medical record data, adjudicated device therapies, and the National Cardiovascular Data Registry ICD Registry. Survival analysis evaluated therapy probability and predictors after ICD implant from 2006 to 2009, with attention to Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups: left ventricular ejection fraction, 31% to 35%; nonischemic cardiomyopathy <9 months' duration; and New York Heart Association class IV heart failure with cardiac resynchronization therapy defibrillator. Among 2540 patients, 35% were <65 years old, 26% were women, and 59% were white. During 27 (median) months, 738 (29%) received ≥1 therapy. Three-year therapy risk was 36% (appropriate, 24%; inappropriate, 12%). Appropriate therapy was more common in men (adjusted hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.43-2.35). Inappropriate therapy was more common in patients with atrial fibrillation (adjusted HR, 2.20; 95% CI, 1.68-2.87), but less common among patients ≥65 years old versus younger (adjusted HR, 0.72; 95% CI, 0.54-0.95) and in recent implants (eg, in 2009 versus 2006; adjusted HR, 0.66; 95% CI, 0.46-0.95). In Centers for Medicare and Medicaid Services Coverage With Evidence Development analysis, inappropriate therapy was less common with cardiac resynchronization therapy defibrillator versus single chamber (adjusted HR, 0.55; 95% CI, 0.36-0.84); therapy risk did not otherwise differ for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups. CONCLUSIONS: In this community cohort of primary prevention patients receiving ICD, therapy delivery varied across demographic and clinical characteristics, but did not differ meaningfully for Centers for Medicare and Medicaid Services Coverage With Evidence Development subgroups.
Assuntos
Arritmias Cardíacas/prevenção & controle , Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis , Cardioversão Elétrica/instrumentação , Prevenção Primária/instrumentação , Disfunção Ventricular Esquerda/terapia , Idoso , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/mortalidade , Arritmias Cardíacas/fisiopatologia , Centers for Medicare and Medicaid Services, U.S. , Cardioversão Elétrica/efeitos adversos , Cardioversão Elétrica/mortalidade , Feminino , Frequência Cardíaca , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Estados Unidos , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/mortalidade , Disfunção Ventricular Esquerda/fisiopatologia , Função Ventricular EsquerdaAssuntos
Cardiologia/normas , Morte Súbita Cardíaca/prevenção & controle , Taquicardia Ventricular/terapia , Fibrilação Ventricular/terapia , Complexos Ventriculares Prematuros/terapia , American Heart Association , Consenso , Medicina Baseada em Evidências/normas , Humanos , Fatores de Risco , Taquicardia Ventricular/complicações , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/mortalidade , Resultado do Tratamento , Estados Unidos , Fibrilação Ventricular/complicações , Fibrilação Ventricular/diagnóstico , Fibrilação Ventricular/mortalidade , Complexos Ventriculares Prematuros/complicações , Complexos Ventriculares Prematuros/diagnóstico , Complexos Ventriculares Prematuros/mortalidadeAssuntos
Cardiologia/normas , Morte Súbita Cardíaca/prevenção & controle , Taquicardia Ventricular/terapia , Fibrilação Ventricular/terapia , Complexos Ventriculares Prematuros/terapia , American Heart Association , Consenso , Medicina Baseada em Evidências/normas , Humanos , Fatores de Risco , Taquicardia Ventricular/complicações , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/mortalidade , Resultado do Tratamento , Estados Unidos , Fibrilação Ventricular/complicações , Fibrilação Ventricular/diagnóstico , Fibrilação Ventricular/mortalidade , Complexos Ventriculares Prematuros/complicações , Complexos Ventriculares Prematuros/diagnóstico , Complexos Ventriculares Prematuros/mortalidadeAssuntos
Arritmias Cardíacas/terapia , Morte Súbita Cardíaca/prevenção & controle , American Heart Association , Arritmias Cardíacas/diagnóstico , Autopsia , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/terapia , Ablação por Cateter , Comorbidade , Morte Súbita Cardíaca/etiologia , Desfibriladores , Eletrocardiografia , Teste de Esforço , Feminino , Coração/diagnóstico por imagem , Humanos , Anamnese , Exame Físico , Gravidez , Prevenção Primária , Qualidade de Vida , Prevenção Secundária , Assistência Terminal , Estados UnidosAssuntos
Arritmias Cardíacas/terapia , Morte Súbita Cardíaca/prevenção & controle , American Heart Association , Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/diagnóstico , Atletas , Autopsia , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/terapia , Ablação por Cateter , Comorbidade , Morte Súbita Cardíaca/etiologia , Desfibriladores , Feminino , Humanos , Gravidez , Prevenção Primária , Qualidade de Vida , Insuficiência Renal Crônica/complicações , Prevenção Secundária , Fatores Sexuais , Assistência Terminal , Estados UnidosAssuntos
Comitês Consultivos , American Heart Association , Cardiologia/normas , Morte Súbita Cardíaca/prevenção & controle , Guias de Prática Clínica como Assunto , Sociedades Médicas , Taquicardia Ventricular/terapia , Morte Súbita Cardíaca/etiologia , Gerenciamento Clínico , Humanos , Taquicardia Ventricular/complicações , Estados UnidosAssuntos
American Heart Association , Terapia de Ressincronização Cardíaca/normas , Cardiologia/normas , Morte Súbita Cardíaca/prevenção & controle , Guias de Prática Clínica como Assunto , Sociedades Médicas , Taquicardia Ventricular/terapia , Comitês Consultivos , Morte Súbita Cardíaca/etiologia , Humanos , Taquicardia Ventricular/complicações , Estados UnidosRESUMO
BACKGROUND: In US clinical practice, many patients who undergo placement of an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden cardiac death receive dual-chamber devices. The superiority of dual-chamber over single-chamber devices in reducing the risk of inappropriate ICD shocks in clinical practice has not been established. The objective of this study was to compare risk of adverse outcomes, including inappropriate shocks, between single- and dual-chamber ICDs for primary prevention. METHODS AND RESULTS: We identified patients receiving a single- or dual-chamber ICD for primary prevention who did not have an indication for pacing from 15 hospitals within 7 integrated health delivery systems in the Longitudinal Study of Implantable Cardioverter-Defibrillators from 2006 to 2009. The primary outcome was time to first inappropriate shock. ICD shocks were adjudicated for appropriateness. Other outcomes included all-cause hospitalization, heart failure hospitalization, and death. Patient, clinician, and hospital-level factors were accounted for using propensity score weighting methods. Among 1042 patients without pacing indications, 54.0% (n=563) received a single-chamber device and 46.0% (n=479) received a dual-chamber device. In a propensity-weighted analysis, device type was not significantly associated with inappropriate shock (hazard ratio, 0.91; 95% confidence interval, 0.59-1.38 [P=0.65]), all-cause hospitalization (hazard ratio, 1.03; 95% confidence interval, 0.87-1.21 [P=0.76]), heart failure hospitalization (hazard ratio, 0.93; 95% confidence interval, 0.72-1.21 [P=0.59]), or death (hazard ratio, 1.19; 95% confidence interval, 0.93-1.53 [P=0.17]). CONCLUSIONS: Among patients who received an ICD for primary prevention without indications for pacing, dual-chamber devices were not associated with lower risk of inappropriate shock or differences in hospitalization or death compared with single-chamber devices. This study does not justify the use of dual-chamber devices to minimize inappropriate shocks.
Assuntos
Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis/efeitos adversos , Insuficiência Cardíaca/terapia , Prevenção Primária/métodos , Sistema de Registros , Idoso , Morte Súbita Cardíaca/epidemiologia , Desenho de Equipamento , Feminino , Insuficiência Cardíaca/mortalidade , Humanos , Incidência , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida/tendências , Resultado do Tratamento , Estados Unidos/epidemiologiaAssuntos
Taquicardia Supraventricular/terapia , Adolescente , Adulto , Fármacos Cardiovasculares/economia , Fármacos Cardiovasculares/uso terapêutico , Ablação por Cateter/economia , Criança , Pré-Escolar , Terapia Combinada , Análise Custo-Benefício , Tomada de Decisões , Técnicas de Diagnóstico Cardiovascular , Gerenciamento Clínico , Eletrocardiografia , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Gravidez , Complicações Cardiovasculares na Gravidez/terapia , Qualidade de Vida , Taquicardia Supraventricular/classificação , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/economia , Taquicardia Supraventricular/epidemiologia , Taquicardia Supraventricular/fisiopatologia , Adulto JovemAssuntos
Taquicardia Supraventricular/terapia , Adolescente , Adulto , Fármacos Cardiovasculares/economia , Fármacos Cardiovasculares/uso terapêutico , Ablação por Cateter/economia , Criança , Pré-Escolar , Terapia Combinada , Análise Custo-Benefício , Tomada de Decisões , Técnicas de Diagnóstico Cardiovascular , Gerenciamento Clínico , Eletrocardiografia , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Gravidez , Complicações Cardiovasculares na Gravidez/terapia , Qualidade de Vida , Taquicardia Supraventricular/classificação , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/economia , Taquicardia Supraventricular/epidemiologia , Taquicardia Supraventricular/fisiopatologia , Adulto JovemAssuntos
American Heart Association , Terapia de Ressincronização Cardíaca/normas , Cardiologia/normas , Ablação por Cateter/normas , Técnicas Eletrofisiológicas Cardíacas/normas , Taquicardia Supraventricular , Adulto , Humanos , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/fisiopatologia , Taquicardia Supraventricular/terapia , Estados UnidosAssuntos
American Heart Association , Terapia de Ressincronização Cardíaca/normas , Cardiologia/normas , Ablação por Cateter/normas , Técnicas Eletrofisiológicas Cardíacas/normas , Taquicardia Supraventricular , Adulto , Humanos , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/fisiopatologia , Taquicardia Supraventricular/terapia , Estados UnidosAssuntos
Cardiologia , Taquicardia Supraventricular , Adulto , American Heart Association , Cardiologia/métodos , Cardiologia/normas , Prática Clínica Baseada em Evidências/organização & administração , Humanos , Guias de Prática Clínica como Assunto , Sociedades Médicas , Taquicardia Supraventricular/classificação , Taquicardia Supraventricular/terapia , Estados UnidosAssuntos
Morte Súbita Cardíaca/prevenção & controle , Eletrocardiografia/métodos , Administração dos Cuidados ao Paciente/métodos , Taquicardia Supraventricular , Adulto , American Heart Association , Cardiologia/métodos , Cardiologia/normas , Morte Súbita Cardíaca/etiologia , Humanos , Taquicardia Supraventricular/classificação , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/etiologia , Taquicardia Supraventricular/terapia , Estados UnidosRESUMO
BACKGROUND: Patient sex and age may influence rates of death after receiving an implantable cardioverter-defibrillator for primary prevention. Differences in outcomes other than mortality and whether these differences vary by heart failure symptoms, etiology, and left ventricular ejection fraction are not well characterized. METHODS AND RESULTS: We studied 2954 patients with left ventricular ejection fraction ≤0.35 undergoing first-time implantable cardioverter-defibrillator for primary prevention within the Cardiovascular Research Network; 769 patients (26%) were women, and 2827 (62%) were aged >65 years. In a median follow-up of 2.4 years, outcome rates per 1000 patient-years were 109 for death, 438 for hospitalization, and 111 for heart failure hospitalizations. Procedure-related complications occurred in 8.36%. In multivariable models, women had significantly lower risks of death (hazard ratio 0.67, 95% CI 0.56 to 0.80) and heart failure hospitalization (hazard ratio 0.82, 95% CI 0.68 to 0.98) and higher risks for complications (hazard ratio 1.38, 95% CI 1.01 to 1.90) than men; patients aged >65 years had higher risks of death (hazard ratio 1.55, 95% CI 1.30 to 1.86) and heart failure hospitalization (hazard ratio 1.25, 95% CI 1.05 to 1.49) than younger patients. Age and sex differences were generally consistent in strata according to symptoms, etiology, and severity of left ventricular systolic dysfunction, except the higher risk of complications in women, which differed by New York Heart Association classification (P=0.03 for sex-New York Heart Association interaction), and the risk of heart failure hospitalization in older patients, which differed by etiology of heart failure (P=0.05 for age-etiology interaction). CONCLUSIONS: The burden of adverse outcomes after receipt of an implantable cardioverter-defibrillator for primary prevention is substantial and varies according to patient age and sex. These differences in outcome generally do not vary according to baseline heart failure characteristics.
Assuntos
Desfibriladores Implantáveis/estatística & dados numéricos , Fatores Etários , Idoso , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/cirurgia , Desfibriladores Implantáveis/efeitos adversos , Feminino , Insuficiência Cardíaca/mortalidade , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Implantação de Prótese/mortalidade , Implantação de Prótese/estatística & dados numéricos , Fatores de Risco , Fatores Sexuais , Estados Unidos/epidemiologiaRESUMO
OBJECTIVES: The purpose of this study was to assess the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in women. BACKGROUND: Clinical trials of primary prevention ICDs enrolled a limited number of women. METHODS: Using a propensity score method, we matched 490 women ≥65 years of age who received an ICD during a hospitalization for heart failure in the National Cardiovascular Data Registry ICD Registry from January 1, 2006, through December 31, 2007, to 490 ICD-eligible women without an ICD hospitalized for heart failure in the Get With The Guidelines for Heart Failure database from January 1, 2006, through December 31, 2009. The primary endpoint was all-cause mortality obtained from the Medicare Claims Database. An identical analysis was conducted in men. RESULTS: Median follow-up for patients with an ICD was 4.6 years versus 3.2 years for patients with no ICD. Compared with women with no ICD, those with an ICD were younger and less frequently white. In the matched cohorts, the survival of women with an ICD was significantly longer than that of women without an ICD (adjusted hazard ratio: 0.79, 95% confidence interval: 0.66 to 0.95; p = 0.013). Similarly, men with an ICD had longer survival than men without an ICD (adjusted hazard ratio: 0.73, 95% confidence interval: 0.65 to 0.83; p < 0.0001). There was no interaction between sex and the presence of an ICD with respect to survival (p = 0.44). CONCLUSIONS: Among older women with left ventricular dysfunction, a primary prevention ICD was associated with a significant survival benefit that was nearly identical to that seen in men. These findings support the use of primary prevention ICDs in eligible patients regardless of sex.
Assuntos
Desfibriladores Implantáveis , Insuficiência Cardíaca/mortalidade , Insuficiência Cardíaca/terapia , Disfunção Ventricular Esquerda/mortalidade , Disfunção Ventricular Esquerda/terapia , Antagonistas Adrenérgicos beta/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Antagonistas de Receptores de Angiotensina/uso terapêutico , Feminino , Humanos , Masculino , Prevenção Primária , Pontuação de Propensão , Sistema de Registros , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Sudden cardiac death is the leading cause of death among end-stage kidney disease patients (ESKD) on dialysis, but the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in this population is uncertain. We conducted this investigation to compare the mortality of dialysis patients receiving a primary prevention ICD with matched controls. METHODS: We used data from the National Cardiovascular Data Registry's ICD Registry to select dialysis patients who received a primary prevention ICD, and the Get with the Guidelines-Heart Failure Registry to select a comparator cohort. We matched ICD recipients and no-ICD patients using propensity score techniques to reduce confounding, and overall survival was compared between groups. RESULTS: We identified 108 dialysis patients receiving primary prevention ICDs and 195 comparable dialysis patients without ICDs. One year (3-year) mortality was 42.2% (68.8%) in the ICD registry cohort compared with 38.1% (75.7%) in the control cohort. There was no significant survival advantage associated with ICD [hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.66-1.13, log-rank P = 0.29]. After propensity matching, our analysis included 86 ICD patients and 86 matched controls. Comparing the propensity-matched cohorts, 1 year (3 years) mortality was 43.4% (74.0%) in the ICD cohort and 39.7% (76.6%) in the control cohort; there was no significant difference in mortality outcome between groups (HR = 0.94, 95% CI: 0.67-1.31, log-rank P = 0.71). CONCLUSIONS: We did not observe a significant association between primary prevention ICDs and reduced mortality among ESKD patients receiving dialysis. Consideration of the potential risks and benefits of ICD implantation in these patients should be undertaken while awaiting the results of definitive clinical trials.
Assuntos
Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis , Insuficiência Cardíaca/complicações , Falência Renal Crônica/complicações , Diálise Renal/métodos , Idoso , Idoso de 80 Anos ou mais , Morte Súbita Cardíaca/epidemiologia , Feminino , Insuficiência Cardíaca/mortalidade , Humanos , Incidência , Falência Renal Crônica/mortalidade , Masculino , Pessoa de Meia-Idade , Prevenção Primária , Pontuação de Propensão , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos RetrospectivosRESUMO
BACKGROUND: Racial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, racial/ethnic minority patients. METHODS AND RESULTS: Data from Get With The Guidelines-Heart Failure Registry and National Cardiovascular Data Registry's ICD Registry were used to perform an adjusted comparative effectiveness analysis of primary prevention ICDs in Medicare, racial/ethnic minority patients (nonwhite race or Hispanic ethnicity). Mortality data were obtained from the Medicare denominator file. The relationship of ICD with survival was compared between minority and white non-Hispanic patients. Our analysis included 852 minority patients, 426 ICD and 426 matched non-ICD patients, and 2070 white non-Hispanic patients (1035 ICD and 1035 matched non-ICD patients). Median follow-up was 3.1 years. Median age was 73 years, and median ejection fraction was 23%. Adjusted 3-year mortality rates for minority ICD and non-ICD patients were 44.9% (95% confidence interval [CI], 44.2%-45.7%) and 54.3% (95% CI, 53.4%-55.1%), respectively (adjusted hazard ratio, 0.79; 95% CI, 0.63-0.98; P=0.034). White non-Hispanic patients receiving an ICD had lower adjusted 3-year mortality rates of 47.8% (95% CI, 47.3%-48.3%) compared with 57.3% (95% CI, 56.8%-57.9%) for those with no ICD (adjusted hazard ratio, 0.75; 95% CI, 0.67%-0.83%; P<0.0001). There was no significant interaction between race/ethnicity and lower mortality risk with ICD (P=0.70). CONCLUSIONS: Primary prevention ICDs are associated with lower mortality in nonwhite and Hispanic patients, similar to that seen in white, non-Hispanic patients. These data support a similar approach to ICD patient selection, regardless of race or ethnicity.
Assuntos
Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis , Cardioversão Elétrica/instrumentação , Etnicidade , Disparidades em Assistência à Saúde/etnologia , Grupos Minoritários , Prevenção Primária/instrumentação , Grupos Raciais , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Pesquisa Comparativa da Efetividade , Morte Súbita Cardíaca/etnologia , Cardioversão Elétrica/efeitos adversos , Cardioversão Elétrica/mortalidade , Humanos , Medicare , Prevenção Primária/métodos , Sistema de Registros , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Patients with heart failure and atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure alone. Yet, the use of anticoagulation therapy varies in clinical practice, especially among older patients, for whom its effectiveness is poorly understood. METHODS AND RESULTS: Using clinical registry data linked to Medicare claims from 2005 to 2011, we examined outcomes of older patients hospitalized with heart failure and atrial fibrillation who newly initiated anticoagulation therapy at discharge. We used Cox proportional hazards models and inverse probability-weighted treatment estimates to adjust for selection bias. Main outcomes were mortality and readmission at 1 and 3 years. Among 5105 patients in 195 hospitals, 1623 (31.8%) started anticoagulation therapy at discharge. Treated patients had lower unadjusted rates of all-cause mortality (26.4% versus 42.8%; P<0.001) and all-cause readmission (58.4% versus 63.7%; P<0.001) at 1 year. After inverse weighting for the probability of treatment and adjustment for other discharge medications, anticoagulation therapy was associated with significantly lower 1-year mortality (hazard ratio, 0.70; 99% confidence interval, 0.59-0.82), but there was no statistically significant difference in the risk of all-cause readmission (hazard ratio, 0.89; 99% confidence interval, 0.78-1.01) or other readmission outcomes. Results were similar at 3 years. CONCLUSIONS: Initiation of anticoagulation therapy at hospital discharge was associated with improved mortality at 1 and 3 years but was not associated with improved cardiovascular readmission among older patients with heart failure and atrial fibrillation.